

Endocrine Therapy for Surgeons: Chemoprevention, Neoadjuvant, and Adjuvant Therapy

Wednesday, May 1, 2019

7:00 AM-12:00 PM

COURSE MODERATORS: J. Michael Dixon, OBE, MD and Ronda Henry-Tillman, MD

FACULTY: J. Michael Dixon, OBE, MD; Ronda Henry-Tillman, MD; Sarah McLaughlin, MD; Tara Sanft, MD

COURSE DESCRIPTION:

This primer course is designed for breast and general surgeons who want to play a larger role in managing endocrine therapy for breast patients. This course will also address the use of chemoprevention for breast cancer risk reduction, use of neoadjuvant and adjuvant endocrine therapy for management of breast cancer, selection of appropriate agents and treatment duration, management of drug-related side effects, and use of ancillary tests to minimize treatment-related complications.

COURSE OBJECTIVES:

At the conclusion of this course, participants should be able to:

- Discuss indications for chemoprevention, where we are today; risk, benefits, and slow uptake
- Summarize benefits to surgeons who provide optional care and treatment in neoadjuvant and adjuvant endocrine chemotherapy in patients who do not receive IV chemotherapy.
- Review and understand ancillary testing needed prior to treatment and how to intervene when results are abnormal

CME Information:

The American Society of Breast Surgeons designates this live activity for a maximum of 4.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Endocrine Therapy for Surgeons: Chemoprevention, Neoadjuvant, and Adjuvant Therapy

Wednesday, May 1, 2019

PRELIMINARY AGENDA

6:30 AM-7:00 AM	Check-in and Breakfast	
7:00 AM-7:30 AM	ER Expression in the Normal Breast and in Breast Cancer: How Should We Measure It? What is ER Positive? Response Rates Related to ER Expression What Endocrine Therapy Agents are Available and How do they Work?	J. Michael Dixon, OBE, MD
7:30 AM-8:00 AM	Options for Chemoprevention in Breast Cancer	Ronda Henry-Tillman, MD
8:00 AM-8:30 AM	Adjuvant Endocrine Therapy for Premenopausal Women with Breast Cancer: Which Agent and for How Long?	Tara Sanft, MD
8:30 AM-9:00 AM	Break	
9:00 AM-9:30 AM	Adjuvant Endocrine Therapy for Postmenopausal Women with Breast Cancer: Which Agent and for How Long?	Sarah McLaughlin, MD
9:30 AM-9:50 AM	Male Breast Cancer: Endocrine Therapy Options	J. Michael Dixon, OBE, MD
9:50 AM-10:10 AM	Neoadjuvant Endocrine Therapy	Sarah McLaughlin, MD
10:10 AM-10:30 AM	Break	
10:30 AM-10:50 AM	Understanding Endocrine Resistance	J. Michael Dixon, OBE, MD
10:50 AM-11:10 AM	Combining Endocrine Therapy With Other Agents (to include Everolimus, CDK4/6 Inhibitors, Parp Inhibitors) in the Future	Tara Sanft, MD
11:10 AM-11:30 AM	Treating Side Effects of Endocrine Therapy	J. Michael Dixon, OBE, MD
11:30 AM-12:00 PM	Case Discussion: Real Cases to be Presented for Audience Participation	Faculty
